E. Tan-chiu

发表

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

C K Redmond, B Fisher, C. Redmond, 1999, Journal of the National Cancer Institute.

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

Greg Yothers, Peter A Kaufman, Norman Wolmark, 2005, The New England journal of medicine.

HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15.

S. Paik, J. Bryant, D. Wickerham, 2000, Journal of the National Cancer Institute.

Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience.

Greg Yothers, Norman Wolmark, Soonmyung Paik, 2002, Journal of the National Cancer Institute.

PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study

I. Bondarenko, H. Iwase, E. Tan-chiu, 2018, British Journal of Cancer.

Effects of tamoxifen on benign breast disease in women at high risk for breast cancer.

S. Paik, J. Costantino, D. Wickerham, 2003, Journal of the National Cancer Institute.

Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes.

N. Wolmark, B. Fisher, E. Fisher, 2001, Journal of the National Cancer Institute.

Reversibility of trastuzumab cardiotoxicity: is the concept alive and well?

E. Tan-chiu, M. Ewer, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER

H. Rugo, Lisa I. Wang, I. C. Tudor, 2011, Clinical Cancer Research.

Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer.

E. Perez, E. Tan-chiu, A. Brufsky, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy

F. André, M. Campone, J. Soria, 2013, Breast Cancer Research and Treatment.

Response to fulvestrant in heavily pretreated postmenopausal women:a single-center experience

S. Franco, C. Vogel, E. Tan-chiu, 2004, Breast Cancer Research and Treatment.

A phase II tolerability trial of neoadjuvant docetaxel with carboplatin and capecitabine in locally advanced breast cancer

S. Franco, C. Vogel, E. Tan-chiu, 2011 .

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.

H. Rugo, L. Amler, H. Burris, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight‐year update of Protocol B‐17

J Costantino, S. Paik, B. Fisher, 1999, Cancer.

Acupuncture for the management of hot flashes in women with early stage breast cancer treated with tamoxifen or an aromatase inhibitor: A pilot study of efficacy, safety and feasibility

S. Franco, C. Vogel, E. Tan-chiu, 2005 .

Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23.

D. Wickerham, N. Wolmark, S. Anderson, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer.

B Fisher, S. Paik, J. Bryant, 1998, Journal of the National Cancer Institute.

Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25.

D. Wickerham, N. Wolmark, S. Anderson, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lower-category benign breast disease and the risk of invasive breast cancer.

S. Paik, J. Costantino, D. Wickerham, 2004, Journal of the National Cancer Institute.

Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.

David A. Smith, A. Tan, C. Fabian, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials.

C. Geyer, N. Wolmark, E. Mamounas, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Breast cancer chemoprevention: current status and future directions.

D. Wickerham, E. Tan-chiu, 2001, Seminars in oncology.

Tamoxifen a nd C hemotherapy f or A xillary N ode-Negative, Estrogen R eceptor-Negativ e B reast C ancer: F indings F rom National S urgical A djuvant B reast a nd B owel P roject B -23

D. Wickerham, N. Wolmark, B. Fisher, 2001 .

Survival of patients with HER2+ metastatic breast cancer and use of trastuzumab following progression: analysis of RegistHER.

M. Birkner, H. Rugo, S. Paik, 2009 .

Phase II study of gemcitabine (Gem) and trastuzumab (T) combination therapy in first line metastatic breast cancer (MBC) patients (pts) with HER2 overexpression.

J. Abraham, E. Tan-chiu, A. Brufsky, 2006, Journal of Clinical Oncology.

Moving Forward: Herceptin® in the Adjuvant Setting

M. Piccart, E. Tan-chiu, 2002, Oncology.

Fifteen‐year prognostic discriminants for invasive breast carcinoma

B Fisher, B. Fisher, E. Fisher, 2001, Cancer.

Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens.

M. Arbushites, S. Stein, K. Blackwell, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Cardiovascular effects of tamoxifen in women with and without heart disease: breast cancer prevention trial. National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial Investigators.

S. Reis, J. Costantino, D. Wickerham, 2001, Journal of the National Cancer Institute.

A phase II study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with HER2+ metastatic breast cancer.

M. Birkner, H. Burris, C. Vogel, 2009 .

Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.

Greg Yothers, Michael Ewer, Norman Wolmark, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer

C. Geyer, N. Wolmark, S. Swain, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trastuzumab plus chemotherapy: convincing survival benefit or not?

C. Vogel, E. Tan-chiu, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lower-Category Benign Breast Disease and the Risk of Invasive Breast Cancer

S. Paik, J. Costantino, D. Wickerham, 2004 .

PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study

I. Bondarenko, H. Iwase, E. Tan-chiu, 2018, British Journal of Cancer.

Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor–Positive/HER2-Negative Advanced or Metastatic Breast Cancer

R. Neuwirth, J. Canon, K. Galinsky, 2021, Clinical Cancer Research.

Zoledronic acid (ZA) effectively inhibits cancer treatment-induced bone loss (CTIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (Let): 12 mos BMD results of the Z-FAST trial

E. Tan-chiu, A. Brufsky, W. G. Harker, 2005 .

Abstract PD1-09: Phase 2 safety and efficacy results of TAK-228 in combination with exemestane or fulvestrant in postmenopausal women with ER-positive/HER2-negative metastatic breast cancer previously treated with everolimus

R. Neuwirth, J. Canon, J. Diamond, 2019, Poster Discussion Abstracts.

Breast cancer chemoprevention: current status and future directions.

D. Wickerham, E. Tan-chiu, 2001, Seminars in oncology.

Burkitt lymphoma Daudi cells contain two distinct farnesyltransferases with different divalent cation requirements.

S. Sebti, A. Hamilton, Y. Qian, 1995, Biochemistry.